Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications
Discover Oncology · 03.09.2025 · 16 (1)
DOI: 10.1007/s12672-025-03431-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 03.09.2025. Verfasst von Lange Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 4000…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Outstanding Youth Science Fund Project of National Natural Science Foundation of China, the China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a clinically aggressive malignancy with high heterogeneity at molecular and genetic levels, which characterized by the absence of effective therapeutic targets and marked resistance to conventional chemotherapy regimens. The androgen receptor (AR) is highly expressed by TNBC tumor cells and plays a vital role on tumor progression. With more research into AR signaling pathways and functions, AR-targeted therapy is becoming a promising treatment strategy. This review synthesizes emerging evidence in AR-related preclinical research and clinical outcomes, including monotherapy and combined strategies based on AR-targeted treatment. Through the comprehensive review, we hope to find novel therapeutic insights for TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
- Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. renqlwu@163.com.
- Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. 1334870996@qq.com.
Förderung
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
- the China Postdoctoral Science Foundation
Zitieren
APA
Ma, L., Xu, H., Wang, C., Hu, Y., Ren, Q., & Yu, S. (2025). Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications. Discover Oncology, 16(1). https://doi.org/10.1007/s12672-025-03431-0
Vancouver
Ma L, Xu H, Wang C, Hu Y, Ren Q, Yu S. Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications. Discover Oncology. 2025;16(1). doi:10.1007/s12672-025-03431-0
BibTeX
@article{Ma2025,
author = {Ma, Lange and Xu, Hao and Wang, Chunyan and Hu, Yue and Ren, Qinglan and Yu, Shengnan},
title = {Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications},
journal = {Discover Oncology},
year = {2025},
volume = {16},
number = {1},
doi = {10.1007/s12672-025-03431-0}
}
EUVIMED